Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLlorian Salvador, Maria
dc.contributor.authorByrne, Eimear M.
dc.contributor.authorSzczepan, Manon
dc.contributor.authorLittle, Karis
dc.contributor.authorChen, Mei
dc.contributor.authorXu, Heping
dc.date.accessioned2022-09-15T06:57:43Z
dc.date.available2022-09-15T06:57:43Z
dc.date.issued2022-07-14
dc.identifier.citationLlorián-Salvador M, Byrne EM, Szczepan M, Little K, Chen M, Xu H. Complement activation contributes to subretinal fibrosis through the induction of epithelial-to-mesenchymal transition (EMT) in retinal pigment epithelial cells. J Neuroinflammation. 2022 Jul 14;19:182.
dc.identifier.issn1742-2094
dc.identifier.urihttp://hdl.handle.net/11351/8194
dc.descriptionInflammation; Macular fibrosis; Subretinal fibrosis
dc.description.abstractBackground We previously reported higher plasma levels of complement fragments C3a and C5a in neovascular Age-related Macular Degeneration (nAMD) patients with macular fibrosis. This study aimed to understand whether complement activation contributes to the development of macular fibrosis and the underlying mechanisms involved. Methods Complement activation was blocked using a C5 neutralizing antibody (BB5.1) in C57BL/6J mice after induction of subretinal fibrosis using the two-stage laser protocol. Fibrotic lesions were examined 10 days after the 2nd laser through fundus examination and immunohistochemistry. The expression of C5aR in fibrotic lesions and retinal pigment epithelial (RPE) cultures were examined by confocal microscopy. Primary murine RPE cells were treated with C3a or C5a (10–100 ng/mL) or TGF-β2 (10 ng/mL). Epithelial-to-mesenchymal transition (EMT) was assessed through various readouts. The expression of E-cadherin, vimentin, fibronectin, α-SMA, Slug, ERK/AKT and pSMAD2/3 were determined by Western blot and immunocytochemistry. Collagen contraction and wound-healing assays were used as functional readouts of EMT. The production of IL-6, TGF-β1, TGF-β2 and VEGF by RPE cells were determined by ELISA. PMX53 was used to block C5aR in RPE cultures and in vivo in mice with subretinal fibrosis. Results Extensive C5b-9 deposition was detected at the site of subretinal fibrosis. BB5.1 treatment completely abrogated complement activation and significantly reduced subretinal fibrosis. C5aR was detected in RPE and infiltrating MHC-II+ cells in subretinal fibrosis. In vitro, RPE cells constitutively express C5/C5a and C5aR, and their expression was increased by TGF-β2 treatment. C5a but not C3a increased fibronectin, α-SMA, vimentin and Slug expression, and decreased E-cadherin expression in RPE cells. C5a treatment also increased the contractility and migration of RPE cells and enhanced the production of VEGF and TGF-β1/2. C5a treatment induced pSmad2/3 and pERK1/2 expression in RPE cells and this was blocked by PMX53. PMX53 treatment significantly reduced sodium fluorescein leakage in the subretinal fibrosis model, while collagen-I+ lesions only mildly reduced. Conclusions Complement activation is critically involved in the development of subretinal fibrosis, partially through C5a–C5aR-mediated EMT in RPE cells. Targeting complement activation rather than C5a may be a novel approach for the management of macular fibrosis.
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofseriesJournal of Neuroinflammation;19
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCèl·lules epitelials
dc.subjectDegeneració macular
dc.subjectUlls - Fibrosi
dc.subject.meshComplement Activation
dc.subject.meshRetinal Pigment Epithelium
dc.subject.meshEpithelial-Mesenchymal Transition
dc.titleComplement activation contributes to subretinal fibrosis through the induction of epithelial-to-mesenchymal transition (EMT) in retinal pigment epithelial cells
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s12974-022-02546-3
dc.subject.decsactivación del complemento
dc.subject.decsepitelio pigmentado de la retina
dc.subject.decstransición epiteliomesenquimatosa
dc.relation.publishversionhttps://doi.org/10.1186/s12974-022-02546-3
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Llorián-Salvador M] The Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry & Biomedical Science, Queen’s University Belfast, Northern Ireland, UK. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Byrne EM] The Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry & Biomedical Science, Queen’s University Belfast, Northern Ireland, UK. Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain. [Szczepan M, Little K, Chen M, Xu H] The Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry & Biomedical Science, Queen’s University Belfast, Northern Ireland, UK
dc.identifier.pmid35831910
dc.identifier.wos000824627500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record